Eli Lilly的股票今年猛涨15%, 尽管主要投资者持有量减少, Eli Lilly's stock surges 15% this year despite reduced holdings by major investors, fueled by strong drug demand.

Eli Lilly和公司股票的大量活动来自各种投资者,例如Rehmann资本咨询组、Emerald共同基金顾问信托和Becker资本管理公司等公司在第四季度减少了其持有量。 Eli Lilly and Company's stock has seen significant activity from various investors, with firms like Rehmann Capital Advisory Group, Emerald Mutual Fund Advisers Trust, and Becker Capital Management reducing their holdings in the fourth quarter. 尽管收入略有下降,公司股票价格今年猛涨15%,原因是对糖尿病和减重药物的需求很高。 Despite a slight earnings miss, the company's stock price has surged 15% this year, driven by high demand for its diabetes and weight-loss drugs. Eli Lilly的市场上限为8 396.4亿美元,P/E比率为75.62。 Eli Lilly's market cap stands at $839.64 billion, with a P/E ratio of 75.62. 该公司还正在开发每日体重减肥药片,或假牙药片,试验结果大有希望。 The company is also developing a daily weight loss pill, orforglipron, with promising trial results. 分析员的平均价格目标是1 000.32美元 Eli Lilly的股票仍然是“机动购买”。 With an average analyst price target of $1,000.32, Eli Lilly's stock remains a "Moderate Buy."